July 6, 2015 / 2:11 PM / 2 years ago

BUZZ-Oncolytics Biotech Inc: Presents mid-stage data on lead drug

** Canadian biotech's U.S.-listed shares up about 25 pct at 67 cents

** Says data from mid-stage study of experimental drug reolysin in combination with chemotherapy gemcitabine suggests increase in median overall survival

** Data indicates combination can also nearly double 1-year survival rates, raise 2-year survival rates by 5 times, compared with gemcitabine alone - COO Matt Coffey

** Up to Thursday's close, stock had fallen nearly 24 pct since April 29, when drug developer announced European regulator had granted reolysin "orphan drug status"

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below